Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeze Group PCLBKK:MEDEZE -1.59%19 EBITDA Margin % is 35.48% as of Jun. 2026, which is 25% below its 10-year median of 47.29. GuruFocus rates BKK:MEDEZE with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Medeze Group PCL ranks better than 91.96% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medeze Group PCL's EBITDA for the
three
months ended in Jun. 2026 was ฿56.5 Mil. Medeze Group PCL's Revenue for the
three
months ended in Jun. 2026 was ฿159.3 Mil. Therefore, Medeze Group PCL's EBITDA margin for the quarter that ended in Jun. 2026 was 35.48%.
Medeze Group PCL (BKK:MEDEZE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medeze Group PCL EBITDA Margin % Related Terms
Medeze Group PCL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medeze Group PCL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:MEDEZE vs HCA, THC, EHC: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Medeze Group PCL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeze Group PCL EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medeze Group PCL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medeze Group PCL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medeze Group PCL (BKK:MEDEZE) has a EBITDA Margin % of 35.48% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medeze Group PCL and its competitors. This is 25% below median its historical median of 47.29. Over the past decade, Medeze Group PCL's EBITDA Margin % has ranged from 31.51 to 49.76. According to the industry distribution chart, Medeze Group PCL ranks #54 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 8%.
Is Medeze Group PCL's EBITDA Margin % too high?
Medeze Group PCL's current EBITDA Margin % of 35.48% is 25% below median its 10-year median of 47.29. Over the past 10 years, this metric has ranged from a low of 31.51 to a high of 49.76. The Healthcare Providers & Services industry median EBITDA Margin % is 10.18. Medeze Group PCL's value of 35.48% is 248.5% above this industry median. Based on the distribution chart, Medeze Group PCL ranks #54 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medeze Group PCL has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medeze Group PCL's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Medeze Group PCL ranks #54 out of 672 companies for EBITDA Margin %. This places Medeze Group PCL in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.18. Medeze Group PCL's value of 35.48% is 248.5% above this benchmark. Historically, Medeze Group PCL's own EBITDA Margin % has ranged from 31.51 to 49.76 over the past decade. While the company's 10-year median is 47.29 vs. the industry median of 10.18, Medeze Group PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.18, based on 672 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeze Group PCL's current EBITDA Margin % of 35.48% is 248.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medeze Group PCL and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeze Group PCL's current EBITDA Margin % is 35.48%, which is 25% below median its own 10-year median of 47.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeze Group PCL stock overvalued right now?
Medeze Group PCL (BKK:MEDEZE) has a current EBITDA Margin % of 35.48%. The current EBITDA Margin % is 35.48%, which is 25% below median its 10-year median of 47.29 and 248.5% above the Healthcare Providers & Services industry median of 10.18. Medeze Group PCL's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medeze Group PCL (BKK:MEDEZE), the current EBITDA Margin % is 35.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment. Geographically, the company operates in Thailand, Vietnam, Cambodia, Philippines, and Other countries, of which maximum revenue is derived from Thailand.
19GF Score
Get the complete analysis for BKK:MEDEZE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:MEDEZE has been successfully added to your 
